Balaji Amines Ltd
Balaji Amines Ltd specialises in manufacturing Methylamines, Ethylamines, Derivatives of specialty chemicals and Pharma Excipients. These have been the main products, it also have facilities for the manufacturing of derivatives, which are down-stream products for various pharma/pesticide industries apart from user specific requirements. It is one of the largest manufacturers of aliphatic amines in India. [1]
- Market Cap ₹ 4,384 Cr.
- Current Price ₹ 1,353
- High / Low ₹ 1,946 / 905
- Stock P/E 26.5
- Book Value ₹ 551
- Dividend Yield 0.81 %
- ROCE 13.4 %
- ROE 9.62 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 21.7%
Cons
- The company has delivered a poor sales growth of 1.03% over past five years.
- Company has a low return on equity of 10.3% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 602 | 632 | 665 | 858 | 947 | 918 | 1,227 | 1,914 | 1,720 | 1,330 | 1,266 | 1,292 | |
| 500 | 503 | 513 | 676 | 753 | 738 | 901 | 1,473 | 1,391 | 1,083 | 1,040 | 1,044 | |
| Operating Profit | 102 | 129 | 151 | 182 | 193 | 180 | 327 | 441 | 330 | 247 | 226 | 247 |
| OPM % | 17% | 20% | 23% | 21% | 20% | 20% | 27% | 23% | 19% | 19% | 18% | 19% |
| 3 | 2 | 9 | 12 | 5 | 10 | 12 | 18 | 10 | 21 | 23 | 28 | |
| Interest | 31 | 20 | 12 | 9 | 13 | 12 | 5 | 7 | 3 | 2 | 2 | 2 |
| Depreciation | 19 | 18 | 18 | 19 | 20 | 24 | 23 | 29 | 31 | 34 | 38 | 46 |
| Profit before tax | 56 | 93 | 130 | 166 | 166 | 154 | 310 | 423 | 305 | 232 | 209 | 227 |
| Tax % | 35% | 34% | 34% | 32% | 29% | 26% | 25% | 27% | 25% | 26% | 25% | 27% |
| 36 | 61 | 86 | 113 | 118 | 114 | 232 | 308 | 228 | 171 | 156 | 166 | |
| EPS in Rs | 11.22 | 18.91 | 26.41 | 34.93 | 36.44 | 35.11 | 71.51 | 95.04 | 70.23 | 52.87 | 48.21 | 51.09 |
| Dividend Payout % | 11% | 11% | 8% | 7% | 8% | 9% | 6% | 6% | 14% | 21% | 23% | 22% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 1% |
| 3 Years: | -9% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -6% |
| 3 Years: | -10% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -11% |
| 3 Years: | -17% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 14% |
| 3 Years: | 10% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 231 | 285 | 371 | 461 | 569 | 661 | 891 | 1,186 | 1,394 | 1,528 | 1,649 | 1,778 |
| 236 | 159 | 103 | 115 | 95 | 102 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 129 | 156 | 175 | 237 | 327 | 334 | 394 | 292 | 151 | 202 | 195 | 238 | |
| Total Liabilities | 603 | 607 | 655 | 819 | 997 | 1,104 | 1,292 | 1,484 | 1,551 | 1,736 | 1,850 | 2,024 |
| 321 | 322 | 309 | 316 | 318 | 363 | 344 | 495 | 604 | 724 | 833 | 883 | |
| CWIP | 3 | 16 | 25 | 66 | 63 | 46 | 173 | 141 | 74 | 143 | 154 | 203 |
| Investments | 30 | 30 | 30 | 66 | 66 | 114 | 66 | 66 | 128 | 66 | 66 | 66 |
| 249 | 238 | 292 | 371 | 550 | 581 | 708 | 782 | 745 | 803 | 797 | 872 | |
| Total Assets | 603 | 607 | 655 | 819 | 997 | 1,104 | 1,292 | 1,484 | 1,551 | 1,736 | 1,850 | 2,024 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | 84 | 72 | 126 | 89 | 148 | 94 | 176 | 187 | 217 | 224 | ||
| -14 | -30 | -23 | -93 | -47 | -130 | -87 | -142 | -155 | -190 | -179 | ||
| -49 | -52 | -54 | -29 | -29 | -31 | 3 | -20 | -22 | -35 | -38 | ||
| Net Cash Flow | -3 | 2 | -5 | 4 | 13 | -13 | 10 | 14 | 10 | -8 | 8 | |
| Free Cash Flow | 52 | 51 | 59 | 58 | 70 | 95 | -37 | 28 | 111 | -5 | 67 | |
| CFO/OP | 68% | 75% | 65% | 93% | 72% | 111% | 40% | 64% | 78% | 107% | 117% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 70 | 69 | 67 | 73 | 64 | 76 | 81 | 83 | 55 | 72 | 71 | 84 |
| Inventory Days | 93 | 62 | 88 | 70 | 100 | 66 | 56 | 69 | 97 | 127 | 129 | 111 |
| Days Payable | 46 | 57 | 55 | 56 | 58 | 40 | 43 | 57 | 13 | 35 | 34 | 26 |
| Cash Conversion Cycle | 117 | 74 | 100 | 87 | 106 | 102 | 94 | 95 | 139 | 164 | 166 | 169 |
| Working Capital Days | 2 | 6 | 31 | 29 | 46 | 46 | 80 | 80 | 98 | 118 | 117 | 112 |
| ROCE % | 19% | 24% | 30% | 33% | 29% | 23% | 38% | 41% | 24% | 16% | 13% | 13% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Aliphatic Amines Sales Volume MT |
|
|||||||||
| Amine Derivatives Sales Volume MT |
||||||||||
| Consolidated Sales Volume MT |
||||||||||
| Specialty Chemicals Sales Volume MT |
||||||||||
| N-Butylamine Capacity Utilization % |
||||||||||
| Total Installed Capacity TPA |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6h - Conference call scheduled for 18 May 2026 at 4:00 PM IST to discuss Q4FY26 results.
-
Corporate Action-Board approves Dividend
8h - Board approved FY26 audited standalone and consolidated results, recommended Rs 11 final dividend, and AGM notice.
-
Board Meeting Outcome for Board Meeting Outcome
8h - Balaji Amines approved FY26 audited results and recommended Rs11 final dividend; AGM notice also approved.
-
Results For The FY2025-26
8h - Board approved FY26 audited standalone and consolidated results; recommended Rs 11 final dividend per share.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 May - Newspaper Advertisement regarding 2nd 100 days Saksham Niveshak Campaign and Special Window for transfer and Dematerialisation of physical shares.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025Transcript PPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT REC
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptPPT
-
May 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Oct 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptAI SummaryPPT
-
Dec 2019Transcript PPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019Transcript PPT
-
Jul 2019TranscriptAI SummaryPPT
-
May 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Feb 2017TranscriptPPT
-
Feb 2017TranscriptPPT
Market Leadership
The company is the largest manufacturer of aliphatic amines and their derivatives in India and the sole producer of a few specialty chemicals. [1]